Search ↗

Comparison

Semaglutide vs Tesamorelin

Semaglutide is GLP-1 & incretins; Tesamorelin is GHRH analogs. They are compared here because they are frequently considered against each other, not because they act alike.

Semaglutide Tesamorelin
Class GLP-1 & incretins GHRH analogs
Evidence Regulator approved Regulator approved
Human trials ~90 ~15
Half-life ~7 days ~26-38 minutes
Reported range 250 mcg - 2.4 mg 1-2 mg
Frequency Once weekly, titrated over 16+ weeks Once daily
Routes Subcutaneous, Oral Subcutaneous
FDA approved Yes Yes
Research use only No No
Banned in sport No Yes
Studied for Type 2 diabetes, Chronic weight management, Cardiovascular risk reduction HIV-associated lipodystrophy, Visceral fat reduction, NAFLD research
Reported side effects Nausea, Vomiting, Diarrhoea, Constipation, Abdominal pain, Injection-site reactions Arthralgia, Injection-site reactions, Peripheral oedema, Myalgia, Impaired glucose tolerance

Semaglutide

Semaglutide is a GLP-1 analog with roughly 94% homology to native GLP-1, modified by substituting alpha-aminoisobutyric acid at position 8 to resist DPP-4 cleavage and by attaching a C18 fatty diacid chain that binds albumin. Together these give a half-life of about a week, allowing once-weekly dosing. It lowers blood glucose through glucose-dependent insulin secretion and glucagon suppression, slows gastric emptying, and acts on hypothalamic appetite centres to reduce energy intake. The STEP trial programme reported mean weight reductions near 15% of body weight at 68 weeks on 2.4 mg weekly.

Tesamorelin

Tesamorelin is GHRH(1-44) with a trans-3-hexenoyl group attached to the N-terminus, a modification that resists degradation by dipeptidyl peptidase-4 and extends its half-life relative to native GHRH. It stimulates pituitary release of growth hormone, raising IGF-1 and preferentially reducing visceral adipose tissue. The visceral-fat selectivity seen in the HIV lipodystrophy trials is the basis of its approval and the reason it is studied separately from other secretagogues.

Semaglutide vs Tesamorelin: common questions

What is the difference between Semaglutide and Tesamorelin?

Semaglutide is GLP-1 & incretins and Tesamorelin is GHRH analogs, so they act on different pathways. Semaglutide: A long-acting GLP-1 receptor agonist and the compound that reset expectations for pharmacological weight loss. Tesamorelin: A stabilised GHRH analog and the only growth-hormone secretagogue with a current FDA approval for a body-composition indication.

Which has stronger evidence, Semaglutide or Tesamorelin?

They sit at the same evidence level: regulator approved. Semaglutide has about 90 human studies and Tesamorelin about 15.

Are Semaglutide and Tesamorelin FDA approved?

Both are FDA approved. Semaglutide: Type 2 diabetes mellitus (Ozempic, Rybelsus); Chronic weight management (Wegovy); Cardiovascular risk reduction in established CVD with overweight or obesity; Reducing the risk of kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (Ozempic, January 2025); Noncirrhotic MASH with moderate to advanced liver fibrosis in adults (Wegovy, accelerated approval August 2025). Tesamorelin: Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

References

Regulatory and primary sources

  1. PubChem compound record (CID 56843331) ↗ · structure, identifiers, synonyms
  2. DailyMed: FDA-approved labeling for Semaglutide ↗ · indications, dosing, warnings as approved
  3. FDA Drugs@FDA database ↗ · approval history
  4. CAS Registry Number 910463-68-2 ↗ · chemical identity
  5. PubChem compound record (CID 16137828) ↗ · structure, identifiers, synonyms
  6. DailyMed: FDA-approved labeling for Tesamorelin ↗ · indications, dosing, warnings as approved
  7. FDA Drugs@FDA database ↗ · approval history
  8. WADA Prohibited List ↗ · current year
  9. CAS Registry Number 218949-48-5 ↗ · chemical identity

Published literature

  1. Wilding JPH, Batterham RL, Davies M, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.Diabetes Obes Metab 2022.PubMed 35441470 · doi:10.1111/dom.14725
  2. Rubino DM, Greenway FL, Khalid U, et al.. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.JAMA 2022.PubMed 35015037 · doi:10.1001/jama.2021.23619
  3. Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity.N Engl J Med 2021.PubMed 33567185 · doi:10.1056/NEJMoa2032183
  4. Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.JAMA 2021.PubMed 33755728 · doi:10.1001/jama.2021.3224
  5. Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.N Engl J Med 2025.PubMed 40353578 · doi:10.1056/NEJMoa2416394
  6. Wharton S, Freitas P, Hjelmesæth J, et al.. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.Lancet Diabetes Endocrinol 2025.PubMed 40961952 · doi:10.1016/S2213-8587(25)00226-8
  7. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.N Engl J Med 2023.PubMed 37952131 · doi:10.1056/NEJMoa2307563
  8. Frías JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med 2021.PubMed 34170647 · doi:10.1056/NEJMoa2107519
  9. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  10. Mayfield CK, Bolia IK, Feingold CL, et al.. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med 2026.PubMed 41476424 · doi:10.1177/03635465251357593
  11. Badran AS, Helal A, Shata KS, et al.. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.Obes Res Clin Pract 2026.PubMed 41545261 · doi:10.1016/j.orcp.2026.01.002
  12. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  13. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.Drugs 2011.PubMed 21668043 · doi:10.2165/11202240-000000000-00000
  14. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.Ann Pharmacother 2012.PubMed 22298602 · doi:10.1345/aph.1Q629
  15. Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci 2026.PubMed 42123471 · doi:10.3390/ijms27093890
  16. Corley MJ, Letendre SL, Nightingale S. CROI 2024: Neuropsychiatric Complications in People With HIV.Top Antivir Med 2024.PubMed 39746672

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.